12:00 AM
 | 
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

RHB-103 regulatory update

RedHill said it and partner IntelGenx plan to submit an NDA to FDA next quarter for RHB-103 to treat migraine based...

Read the full 84 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >